Head and Neck Cancer Free Sample Report.
By Dominique Fontanilla, Senior Analyst
30 November 2015
I joined Datamonitor Healthcare’s disease team in 2014 having previously worked as a biochemistry postdoctoral fellow ...
Read full bio
Datamonitor Healthcare has reviewed candidates that are undergoing treatment developments within the head and neck cancer market, across the US, Japan, and the five major EU markets (France, Germany, Italy, Spain, and the UK).
Our sample Head and Neck cancer (SCCHN) report offers a preview of the market from 2015 to 2024, giving you an understanding of:
- Growth expectations in the combined SCCHN market
- How increasing incidence of SCCHN and the uptake of newly approved therapies affects this growth
- How the revenue from new brands will offset the biosimilar and generic erosion of Erbitux and TS-1, enabling the net growth of the market
Fill out the form now to download your exclusive sneak peek into this market leading report >>
If you’re already a subscriber to Datamonitor Healthcare, click here to access the full report.